Amaya Advisory Cmte. Will Grapple With Standards For Novel Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Walking improvement in MS would give Acorda a unique claim, but FDA notes that "novel endpoints may pose clinical interpretation issues, and may turn out to be less than satisfactory."